VRTX — Vertex Pharmaceuticals Incorporated Share News
0.000.00%
Last trade - 00:00- $128.95bn
- $121.10bn
- $12.00bn
Vertex's kidney disease drug meets main goal in late-stage trial (updated)
Vertex's kidney disease drug meets main goal in late-stage trial
U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR
Vertex Pharmaceuticals falls after Q4 profit miss
Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments
Brief: Vertex Pharmaceuticals Q4 Adjusted EPS USD 5.03 Vs. IBES Estimate USD 5.07
U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla
U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin
U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge
Citi sees momentum in US pharma and biotech into 2026, updates ratings on top picks
U.S. STOCKS ON THE MOVE-Snowflake, Hecla Mining, Newmont
U.S. STOCKS ON THE MOVE-Vertex, Nike, Intel
U.S. STOCKS ON THE MOVE-Vertex, Nike, Intel
Leerink Partners lifts Vertex price target on pipeline optimism
U.S. RESEARCH ROUNDUP-Incyte, ServiceNow, Spire Global
Vertex's gene therapy shows promise in younger children with blood disorders
CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study
US FDA awards six more fast-track vouchers to speed drug reviews (updated)
US FDA awards six more fast-track vouchers to speed drug reviews (updated)